艾沙康唑在儿童毛霉病治疗中的研究进展与临床思考

doi:10.12372/jcp.2026.25e0937

Abstract

Abstract:

Mucormycosis is an infectious disease caused by fungi in the order Mucorales. Due to its high mortality rate and limited treatment options, treating mucormycosis in children remains challenging. Isavuconazole, a novel triazole antifungal agent, has offered a new option for treating mucormycosis. Though isavuconazole has been approved for marketing in China, data on its use in pediatric mucormycosis remain extremely limited. This article reviews the research progress of isavuconazole in treating pediatric mucormycosis, introduces its mechanism of action, pharmacokinetics, and comparison with other antifungal drugs. It also analyzes the potential efficacy and safety of isavuconazole in treating pediatric mucormycosis, and discusses its dosage and administration in children and the necessity of therapeutic drug monitoring, thus providing references for the clinical use of therapeutic drugs in pediatric mucormycosis.

Key words: isavuconazole, mucormycosis, child

CLC Number:

SHI Jiena, ZHANG Junqi, SHEN Longhui. Research progress and clinical implications of isavuconazole in the treatment of pediatric mucormycosis[J].Journal of Clinical Pediatrics, 2026, 44(6): 589-594.

Figures/Tables 2

References 21

[1]	中国医药教育协会真菌病专业委员会, 中国毛霉病专家共识工作组. 中国毛霉病临床诊疗专家共识(2022)[J]. 中华内科杂志, 2023, 62(6) : 597-605.
	Medical Mycology Society of Chinese Medicine and Education Association, Chinese Mucormycosis Expert Consensus Group. Expert consensus on diagnosis and management of mucormycosis in China (2022)[J]. Zhonghua Neike Zazhi, 2023, 62(6): 597-605.
[2]	Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium[J]. Lancet Infect Dis, 2019, 19(12): e405-e421.
[3]	中华医学会血液学分会抗感染学组. 艾沙康唑临床应用专家共识(2023版)[J]. 临床血液学杂志, 2023, 36(5): 295-302.
	Anti Infection Group, Chinese Society of Hematology, Chinese Medical Association. Consensus recommendations for the clinical application of isavuconazole (2023)[J]. Linchuang Xueyexue Zazhi, 2023, 36(5): 295-302.
[4]	Badali H, Cañete-Gibas C, McCarthy D, et al. Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States[J]. J Clin Microbiol, 2021, 59(9): e0123021.
[5]	Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7): 828-837.
[6]	Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system[J]. Med Mycol, 2020, 58(4): 417-424.
[7]	Qin J, Bi H, Tang G, et al. Real-world effectiveness and safety of isavuconazole versus amphotericin B for patients with invasive mucormycosis[J]. Microorganisms, 2025, 13(1): 55.
[8]	Groll AH, Townsend R, Desai A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4[J]. Transpl Infect Dis, 2017, 19(5): e12751.
[9]	Van Matre ET, Evans SL, Mueller SW, et al. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center[J]. Ann Clin Microbiol Antimicrob, 2019, 18(1): 13.
[10]	Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients[J]. Antimicrob Agents Chemother, 2021, 65(8): e0029021.
[11]	Segers H, Deville JG, Muller WJ, et al. Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial[J]. Antimicrob Agents Chemother, 2024, 68(12): e0048424.
[12]	Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients[J]. Pediatr Infect Dis J, 2020, 39(8): 718-724.
[13]	Gunathilaka SS, Keragala RK, Gunathilaka KM, et al. Use of isavuconazole in mucormycosis: a systematic review[J]. BMC Infect Dis, 2025, 25(1): 25.
[14]	崔颖, 钟旭丽, 刘碧晴, 等. 艾沙康唑治疗儿童造血干细胞移植围手术期肺毛霉病一例[J]. 临床药物治疗杂志, 2024, 22(2): 87-89.
	Cui Y, Zhong XL, Liu BQ, et al. Isavuconazole in the treatment of pulmonary mucormycosis in children undergoing hematopoietic stem cell transplantation: a case report[J]. Linchuang Yaowu Zhiliao Zazhi, 2024, 22(2): 87-89.
[15]	U.S.Food and Drug Administration. CRESEMBA label[EB/OL]. [2025-03-24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207500s016,207501s016lbl.pdf.
[16]	European Medicines Agency. CRESEMBA label[EB/OL].[2025-07-24]. https://www.ema.europa.eu/en/documents/product-information/cresemba-epar-product-information_en.pdf.
[17]	Andes D, Kovanda L, Desai A, et al. Isavuconazole concentration in real-world practice: consistency with results from clinical trials[J]. Antimicrob Agents Chemother, 2018, 62(7): e00585.
[18]	Fernández Ledesma B, Mendoza-Palomar N, Melendo Pérez S, et al. Isavuconazole use and TDM in real-world pediatric practice[J]. Antimicrob Agents Chemother, 2023, 67(12): e0082923.
[19]	Jendoubi A, Pressiat C, De Roux Q, et al. The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: a systematic review[J]. Int J Antimicrob Agents, 2024, 63(2): 107078.
[20]	Biagi M, Butler D, Tan X, et al. Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2019, 63(12): e01085.
[21]	Perez L, Corne P, Pasquier G, et al. Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and monte carlo simulations of high off-label doses[J]. J Fungi (Basel), 2023, 9(2): 211.

剂型	年龄	体重	负荷剂量	维持剂量
注射剂（以硫酸艾沙康唑鎓计）	1~<3岁	<18 kg	每次15 mg/kg，q8h，共6次	每次15 mg/kg，qd
	3~<18岁	<37 kg	每次10 mg/kg，q8h，共6次	每次10 mg/kg，qd
	3~<18岁	≥37kg	每次372 mg，q8h，共6次	每次372 mg，qd
胶囊（以硫酸艾沙康唑鎓计）	6~<18岁	16~<18 kg	每次149 mg，q8h，共6次	每次149 mg，qd
		18~<25 kg	每次233.5 mg，q8h，共6次	每次233.5 mg，qd
		25~<32 kg	每次298 mg，q8h，共6次	每次298 mg，qd
		≥32 kg	每次372 mg，q8h，共6次	每次372 mg，qd

剂型	年龄	体重	负荷剂量	维持剂量
注射剂（以艾沙康唑计）	1~<18岁	<37 kg	每次5.4 mg/kg，q8h，共6次	每次5.4 mg/kg，qd
注射剂（以艾沙康唑计）	1~<18岁	≥37 kg	每次200 mg，q8h，共6次	每次200 mg，qd
胶囊（以艾沙康唑计）	6~<18岁	16~<18 kg	每次80 mg，q8h，共6次	每次80 mg，qd
		18~<25 kg	每次120 mg，q8h，共6次	每次120 mg，qd
		25~<32 kg	每次160 mg，q8h，共6次	每次160 mg，qd
		32~<37 kg	每次180 mg，q8h，共6次	每次180 mg，qd
		≥37 kg	每次200 mg，q8h，共6次	每次200 mg，qd

Research progress and clinical implications of isavuconazole in the treatment of pediatric mucormycosis

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 21

Related Articles 15

Metrics

Comments

Recommended 0

[1]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[2]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.
[3]	LI Jian, LI Tao, HE Lulu, WU Lei, HU Tianjiao, HUANG Yixuan, LIN Xinrong, SHEN Qiyang, PAN Sirui, XIE Nan, ZHOU Jianfeng, ZHOU Chunlei, ZHOU Li. A retrospective analysis of 50 cases of malignant rhabdoid tumor in children: clinical features, treatment response and prognostic factors [J]. Journal of Clinical Pediatrics, 2026, 44(6): 499-507.
[4]	LI Yanhua, ZHANG Huanhuan, YANG Jingwei, LIAO Xuelian, SHAO Jingbo, JIAO Yangyang, ZHANG Ting, HUANG Can, JIANG Shayi. Analysis of survival prognosis and related risk factors of pediatric head and neck rhabdomyosarcoma [J]. Journal of Clinical Pediatrics, 2026, 44(6): 518-523.
[5]	SHI Yongyuan, YANG Lijuan, LEI Wenting, XIONG Yurong, PAN Shujing, LI Yuelin, ZHANG Jiali, TIAN Maoqiang. Clinical characteristics and prognosis analysis of autoimmune encephalitis with movement disorders in children: A single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 532-539.
[6]	GU Xinjia, ZHENG Zhihui, MEI Lingli, ZHENG Jinxin, LIU Taixiang, ZHU Jihua. Burden of urinary system diseases in children and adolescents in China, 1990-2023 [J]. Journal of Clinical Pediatrics, 2026, 44(6): 546-555.
[7]	CHEN Xumei, AIERKEN Aibibai, YUE Xueyan, RU Liang, ZHANG Li. A study on the latent profile analysis of psychological resilience and coping styles of parents of children with asthma and its influencing factors [J]. Journal of Clinical Pediatrics, 2026, 44(6): 556-563.
[8]	LUO Zihao, LI Shaojun, REN Peizhen, WANG Yanhong, GENG Gang. Analysis of clinical characteristics of children with pneumonia complicated with plastic bronchitis and establishment and validation of risk prediction model [J]. Journal of Clinical Pediatrics, 2026, 44(6): 564-572.
[9]	CHU Weihong, XU Liyan, PENG Shao, LAI Jianming. Lower extremity arterial thrombosis as first clinical manifestation in children's systemic lupus erythematosus complicated with antiphospholipid syndrome: a two-case report [J]. Journal of Clinical Pediatrics, 2026, 44(6): 579-583.
[10]	CHEN Liuwang, LIU Pan, XI Rongjuan, ZHANG Xianxia, ZHANG Yi, WEI Xingjiao, SU Min, YANG Yonghong, FU Yangxi. Methylmalonic acidemia with homocystinemia causing subacute combined degeneration of the spinal cord : a case report [J]. Journal of Clinical Pediatrics, 2026, 44(6): 584-588.
[11]	Professional Committee of Child Allergology, China Maternal and Child Health Association, Dermatology and Venereology Group of Pediatric Branch Society, Chinese Medical Association: Editorial Board of the Journal of Clinical Pediatrics. Expert consensus on non-pharmacological interventions for atopic dermatitis in children [J]. Journal of Clinical Pediatrics, 2026, 44(5): 381-393.
[12]	ZHAO Xinrong, XU Zigang. Molecular mechanisms, diagnosis, and treatment of skin disorders associated with CARD14 mutations [J]. Journal of Clinical Pediatrics, 2026, 44(5): 399-404.
[13]	HAO Yanzhao, LI Wanyue, LI Jianguo, DOU Jinfa, YU Huiqian, WANG Jianbo. Short-term efficacy and recurrence risk of dupilumab in the treatment of moderate to severe atopic dermatitis in children: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(5): 412-417.
[14]	DONG Ying, CAO Tingting, WU Jianping, ZHANG li, GE Hongsong. Dermoscopic characteristics analysis of acral volar melanocytic nevi in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(5): 418-423.
[15]	HUANG Shuyue, CHENG Ming, WANG Xi′ou, SONG Yi, DU Mu, SONG Fuying, CAO Bingyan. Clinical features of fructose-1,6-bisphosphatase deficiency in 4 children and literature review [J]. Journal of Clinical Pediatrics, 2026, 44(5): 438-444.